The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The ongoing Phase III CELESTIAL-RRCLL trial: sonrotoclax plus anti-CD20 antibody in R/R CLL/SLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the ongoing Phase III CLL-RR1/CELESTIAL-RRCLL trial (NCT06943872), which will investigate sonrotoclax plus anti-CD20 antibody therapies versus venetoclax plus rituximab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Dr Eichhorst highlights the fourth arm of the study that will allow patients to stop treatment with sonrotoclax earlier if undetectable measurable residual disease (MRD) is achieved. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CLLRR or CLLRR1 study is a Phase III trial. Our study group and other study groups are doing it in cooperation with BeOne in order to evaluate the BCL2 inhibitors sonrotoclax in combination with rituximab or obinutuzumab and comparing that to the standard venetoclax plus rituximab. And interestingly there’s a fourth arm in that study as well which I think is the most interesting one for patients because here we will evaluate MRD guided treatment with the option to stop the 24 cycles of treatment with sonrotoclax earlier in case patients achieve undetectable MRD with sonrotoclax plus rituximab antibody treatment...
CLLRR or CLLRR1 study is a Phase III trial. Our study group and other study groups are doing it in cooperation with BeOne in order to evaluate the BCL2 inhibitors sonrotoclax in combination with rituximab or obinutuzumab and comparing that to the standard venetoclax plus rituximab. And interestingly there’s a fourth arm in that study as well which I think is the most interesting one for patients because here we will evaluate MRD guided treatment with the option to stop the 24 cycles of treatment with sonrotoclax earlier in case patients achieve undetectable MRD with sonrotoclax plus rituximab antibody treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
